The doped Olympics were a commercial
Posted on: 30 May 2026
On Sunday 24 May, in a Las Vegas casino, forty-two athletes competed under the Enhanced Games banner with no anti-doping controls. A single world record fell, the fifty-metre freestyle, lowered by seven hundredths of a second by Greek swimmer Kristian Gkolomeev, who had never reached the podium in four Olympic attempts. Twelve other athletes improved their personal best. Prize money was $250,000 per event, with a $1 million bonus for breaking a world record. Reactions from the sporting world ranged from WADA's condemnation to European press sarcasm, with the epithet "Roman circus" circulating more than once. Public debate polarised predictably, split between those who saw an assault on sporting ethics and those invoking bodily autonomy as an inviolable right. Let me try to look elsewhere, because the real game is not on the track.
Enhanced Group, the company organising the event, is listed on Nasdaq through a SPAC merger with A Paradise Acquisition Corp at a valuation of $1.3 billion. In the first quarter of 2026 it generated $2,755 in revenue. The 2028 projection is $357 million, split into $110 million from prescription drugs, $140 million from over-the-counter supplements, and $107 million from sports. Translated: the sporting event is a minor line item in the business plan, while the actual product is the direct-to-consumer platform selling peptides, hormone replacement therapies, and longevity drugs. CEO Maximilian Martin, former Morgan Stanley with a €400 million digital exit, said it explicitly to Benzinga last April: "the brand attracts attention, the athletes provide real-world proof, the Games generate cultural relevance, and the IRB-approved dataset creates defensible clinical intelligence over time. The Enhanced Games makes this philosophy visible, while our DTC platform makes it accessible." The headline of the publication that interviewed him was even blunter: the performance-medicine platform, not the Games themselves, is the real prize.
To grasp the scale of what we are watching one has to descend a level, and Martin explains it with disarming candour: "if I want to advertise peptides, the Meta algorithm will only put me in front of people already interested. What it will never do is put me in front of a forty-year-old who has never heard of peptides in his life. How do I reach that person? Through sport." Six hundred million social media views over the past twelve months confirm the logic works. The forty-two athletes in Las Vegas are not the product, they are the customer acquisition cost of a consumer market Enhanced estimates at $325 billion globally. Sport, the last institution capable of producing globally legitimised public spectacle, has been converted into an advertising channel for a publicly-listed pharmaceutical industry selling peptides, testosterone, GLP-1s, longevity therapies. Principal investors include Peter Thiel, Donald Trump Jr's 1789 Capital fund, the Winklevoss twins, and a Saudi prince. Co-founder Christian Angermayer, interviewed by Vanity Fair, declared his personal weekly pharmacological stack: 250 milligrams of testosterone, tesamorelin, SS-31, DHEA, Jardiance, GLP-1s. He is not an external investor, he is the ideal customer of his own product.
So far the facts, verifiable, openly declared by the company in SEC filings. Now the clinical part, which is where things become genuinely interesting.
The question no one asks publicly, because everyone is busy arguing about real Olympics versus fake ones, is simple: does this stuff cause harm in the long term? The honest answer is we don't know, and we won't know for at least ten or fifteen years. Tesamorelin is FDA-approved for lipodystrophy in HIV-positive patients, a therapeutic indication in a pathological population. Using it for athletic amplification in healthy adults is another matter entirely, and shifts the burden of proof of safety from the regulator to the prescriber. CJC-1295, one of the compounds Enhanced already has in its pipeline, has received specific FDA safety warnings including serious adverse events such as increased heart rate and systemic vasodilatory reactions. Animal literature on long-term GH administration signals diabetes, fluid retention, cardiomyopathy, hypertension, osteoporosis. Human literature is fragmentary and largely limited to short-term pharmacokinetic studies rather than long-term outcome data, as even the websites selling these compounds openly admit.
A provocation imposes itself, and it is honest to put it on the table rather than avoid it. Forty-two declared dopers produced a single world record. Olympic athletes deemed clean produce records regularly, if not frequently. One could read this as evidence that doping works poorly, or as evidence that Olympic athletes are doping and not declaring it, but both readings would be naive. The more uncomfortable reading is different: doping has a multiplicative effect, not a substitutive one, and a second-tier athlete chemically enhanced approaches the level of a first-tier athlete without surpassing him. Enhanced Games recruited Gkolomeev, never on the podium across four Olympic Games, and brought him to break a world record by seven hundredths of a second. The previous record belonged to Cameron McEvoy, Australian, classified among the clean athletes of the FINA system. It might be interesting to ask how clean the athletes setting world records actually are, considering that Lance Armstrong won seven Tours de France passing hundreds of anti-doping controls, that Russia ran a state-sponsored doping system across two Olympic Games before being caught, and that the Marion Jones BALCO case in 2007 revealed an entire pharmaceutical supply chain operating across the upper tiers of American athletics. The difference between Olympic athletes and Enhanced athletes may not be doping itself, but the sophistication of concealment. If that is the case, then the Enhanced Games are not introducing anything new to sport, they are simply removing the veil from what was already there.
The crudest epidemiological data we have comes from American professional wrestling. A study by Eastern Michigan University analysed wrestlers active between 1985 and 2011: overall mortality up to 2.9 times the general population, cardiovascular mortality 15.1 times higher, overdose mortality 122.7 times higher, cancer mortality 6.4 times higher. Wrestlers are not Olympic athletes and the data includes head trauma and painkiller abuse, but they are the natural clinical case study of what happens when professional athletes use cocktails of hormones and performance drugs for decades with variable medical supervision. It is the closest dataset we have to the Enhanced experiment.
There is also a historical memory worth recovering. Tom Simpson, British cyclist, collapsed and died on Mont Ventoux during the 1967 Tour de France with amphetamines in his bloodstream. Lance Armstrong, dismantled in 2012 after a decade of denials, the entire generation of professional cyclists from the EPO era now suffering chronic cardiovascular conditions in their fifties and sixties. The bodybuilders of the eighties and nineties with anomalous mortality rates for their age cohort. The compound effects of performance pharmacology are slow, statistical, and become visible decades later, when those who sold have already cashed out and those who consumed have already raised children, built careers, accumulated wealth or debt, and cannot go back.
The real structural mechanism, and here lies the falsifiable part of my thesis, is a temporal asymmetry between revenue and harm. Enhanced Group projects $357 million in revenue by 2028. The first consumer customers from 2026 will be just entering their third year of use. The moment when any signals of cumulative harm emerge, if they do, will coincide with the moment when the founders have already exercised their stock options. The pattern is structurally identical to what we have already seen in other markets. Philip Morris was selling cigarettes in 1965, the class action lawsuits arrived in the 1990s and 2000s. Purdue Pharma was selling OxyContin from 1996, the bankruptcy settlement came in 2019 after six hundred thousand American overdose deaths. Turner & Newall sold asbestos products across Britain for decades, the mesothelioma diagnoses arrived when the workers were already retired or dying. The model is proven: harm emerges outside the responsibility horizon of those who sold, and the cost is externalised to the public health system and to the families of the consumers. The novelty of Enhanced is not the structure, it is the product: for the first time we are watching this architecture applied openly, publicly, and through a listed entity, to the biological amplification of the healthy body.
The Overton point I had in mind when starting research for this piece operates, but on a different axis from what it appears. It is not normalising Olympic doping, which is a marginal matter of interest to forty-two people and a handful of sports journalists. It is normalising something much larger: the substitution of medicine of disease with medicine of performance, where the consumer is no longer a patient but a client of an amplification market, and where the category of "health" itself ceases to mean absence of pathology and comes to mean continuous optimisation. The forty-year-old paying eight thousand pounds a month at Harley Street, Mayfair or Beverly Hills clinics for longevity therapies does not think of himself as a patient, he thinks of himself as an investor in himself. Enhanced Games is simply exporting that mentality from the luxury segment to the mass market through the Meta algorithm, using sport as a legitimising device because sport remains the only institution that algorithmic suspicion filters cannot reach.
Let me be clinically precise on the falsifiability point, because without it I would be doing prophecy rather than analysis. My thesis holds if over the next ten or fifteen years we see three things. First: measurable increases in NHS and equivalent public health expenditure for cardiovascular, endocrine, and oncological conditions in cohorts of men between forty and sixty using hormonal therapies and peptides, statistically separable from general population ageing trends. Second: the emergence of class actions or substantive epidemiological literature connecting specific compounds marketed today to specific harm outcomes. Third: the progressive rotation of health language from "cure" to "optimisation" in institutional contexts, indicating that the Overton window has actually shifted. If none of these three things happens, I will have been wrong. If only some occur, the pattern was weaker than I described. If all three occur, the Enhanced Games of 2026 will be remembered as the moment this industry came out into the open, not as the marginal event it appears to be today.
A question remains open, and honestly I cannot resolve it. It is possible that some of these compounds are genuinely safe and useful in the long term, and that my scepticism is a conservative reflex of the same mental category that fifty years ago rejected the contraceptive pill or forty years ago rejected in vitro fertilisation. I lack the epidemiological tools to distinguish today which fraction of this industry is legitimate medical innovation and which is commercial cover for unevaluated risks. What I can say with confidence is that the business model commercialising these compounds, built on sport as advertising, peptides as product, and stock market listing as exit, is not designed to discover the difference between the two. It is designed to monetise before the difference emerges.
On Sunday in Las Vegas we did not witness a race, we witnessed a $31 million advertising spot for a $325 billion consumer market, with products whose long-term effects are unknown by design, because by design they will remain so until it is too late for those who will have consumed them.